CureVac N.V.

NASDAQ:CVAC

2.74 (USD) • At close September 6, 2024
Bedrijfsnaam CureVac N.V.
Symbool CVAC
Munteenheid USD
Prijs 2.74
Beurswaarde 614,598,440
Dividendpercentage 0%
52-weken bereik 2.215 - 8.93
Industrie Biotechnology
Sector Healthcare
CEO Dr. Alexander Zehnder M.B.A., M.D.
Website https://www.curevac.com

An error occurred while fetching data.

Over CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial

Vergelijkbare Aandelen

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

86.43 USD

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

54.09 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

45.52 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

96.58 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

55.24 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

19.72 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Natera, Inc. logo

Natera, Inc.

NTRA

112.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)